Pure Global AI
NCT06406569Not yet recruiting

A Qualitative and Usability Evaluation of Advanced Technologies for Home Upper Limb Neurorehabilitation Post-stroke

Home RehabGym: a Qualitative and Usability Evaluation of Advanced Technologies for Home Upper Limb Neurorehabilitation Post-stroke
Tan Tock Seng HospitalClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Stroke
Drug/Device/Intervention
H-Man Robot
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Tan Tock Seng Hospital
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2024
End date
Feb 01, 2025
Enrollment
30 participants
Primary outcome

Compliance Rates

Summary

Due to limited resources such as the low therapist to patient ratio or high costs associated
 to rehabilitation therapy, providing higher therapy dose to patients after discharge is
 highly challenging. This often results in non-use of the impaired limb as a result of the
 decreased therapy dose, causing partial loss of the functional improvements previously gained
 during early rehabilitation.
 
 In this study, the investigators plan to pilot the HomeRehab Gym concept via the deployment
 of three rehabilitation devices at patients' homes: MyoPanda, H-Man and ReHandyBot.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionFamily history of strokeCerebral infarction, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06406569
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06406569 through Pure Global AI's free database. This phase not specified trial is sponsored by Tan Tock Seng Hospital and is currently Not yet recruiting. The study focuses on Stroke. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.